RGD Reference Report - Antagonism of TIM-1 blocks the development of disease in a humanized mouse model of allergic asthma. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Antagonism of TIM-1 blocks the development of disease in a humanized mouse model of allergic asthma.

Authors: Sonar, SS  Hsu, YM  Conrad, ML  Majeau, GR  Kilic, A  Garber, E  Gao, Y  Nwankwo, C  Willer, G  Dudda, JC  Kim, H  Bailly, V  Pagenstecher, A  Rennert, PD  Renz, H 
Citation: Sonar SS, etal., J Clin Invest. 2010 Aug 2;120(8):2767-81. doi: 10.1172/JCI39543. Epub 2010 Jul 12.
RGD ID: 5128851
Pubmed: PMID:20628202   (View Abstract at PubMed)
PMCID: PMC2912180   (View Article at PubMed Central)
DOI: DOI:10.1172/JCI39543   (Journal Full-text)

Studies in mice and humans have revealed that the T cell, immunoglobulin, mucin (TIM) genes are associated with several atopic diseases. TIM-1 is a type I membrane protein that is expressed on T cells upon stimulation and has been shown to modulate their activation. In addition to a recently described interaction with dendritic cells, TIM-1 has also been identified as a phosphatidylserine recognition molecule, and several protein ligands have been proposed. Our understanding of its activity is complicated by the possibility that TIM-1 possesses multiple and diverse binding partners. In order to delineate the function of TIM-1, we generated monoclonal antibodies directed to a cleft formed within the IgV domain of TIM-1. We have shown here that antibodies that bind to this defined cleft antagonize TIM-1 binding to specific ligands and cells. Notably, these antibodies exhibited therapeutic activity in a humanized SCID model of experimental asthma, ameliorating inflammation, and airway hyperresponsiveness. Further experiments demonstrated that the effects of the TIM-1-specific antibodies were mediated via suppression of Th2 cell proliferation and cytokine production. These results demonstrate that modulation of the TIM-1 pathway can critically influence activated T cells in a humanized disease model, suggesting that TIM-1 antagonists may provide potent therapeutic benefit in asthma and other immune-mediated disorders.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
asthma  IEP 5128851 RGD 
asthma  ISOHAVCR1 (Homo sapiens)5128851; 5128851 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Havcr1  (hepatitis A virus cellular receptor 1)

Genes (Mus musculus)
Havcr1  (hepatitis A virus cellular receptor 1)

Genes (Homo sapiens)
HAVCR1  (hepatitis A virus cellular receptor 1)


Additional Information